India and Belgium Unite to Advance RNA-Based Vaccines

MoU Signed Between Techinvention and Quantoom Biosciences, in the presence of Her Royal Highness Princess Astrid of Belgium during the Belgian Economic Mission to India Thursday, March 6, 2025 TechInvention Lifecare Pvt. Ltd. (TechInvention) is proud to announce a strategic collaboration with Belgium-based Quantoom Biosciences (Quantoom). The Memorandum of Understanding (MoU) was formally signed during the Belgian Economic Mission to India on Tuesday, March 4, 2025, in the presence of Her Royal Highness Princess Astrid of Belgium, industry leaders and key stakeholders from both nations.
As part of this collaboration, TechInvention is introducing Quantoom’s cutting-edge RNA manufacturing solutions—to India with a strong focus on accessibility, scalability, and affordability.

This advanced suite of technologies is designed to de-risk and accelerate the development of RNA-based vaccines. Complementing this, TechInvention will leverage its translational research expertise, regulatory know-how, and GMP manufacturing capabilities to streamline developing, scaling, and commercialising novel RNA-based products. This partnership represents a transformative milestone in India’s biotechnology landscape, establishing end-to-end mRNA production capabilities at TechInvention’s forthcoming EU-GMP-approved facility, the Global Collaborative Centre for Medical Countermeasures (GCMC), in Mumbai.
With a One Health approach, this collaboration extends beyond human health to encompass animal and environmental health. The technology is designed for environmental sustainability, integrating modular, low-carbon-footprint mRNA systems that support global decarbonization efforts. It aligns with worldwide initiatives to enable access to next-generation RNA technologies, ensuring that low-and middle-income countries (LMICs) benefit from locally manufactured, cost-effective, and scalable solutions.
José Castillo, CEO, Quantoom Biosciences, added: "At Quantoom, our mission is to enable our partners to accelerate their m(sa)RNA-based vaccines development, thanks to our end-to-end N-Force Toolbox. We think that our technology will, by design, make RNA products accessible and scalable globally. Partnering with TechInvention in India is a vital step toward achieving this goal, into the most populated country in the world, and we look forward to enabling groundbreaking developments in the field of RNA-based medicines."
Syed Ahmed, Director & CEO, TechInvention, commented: "We are excited to bring Quantoom’s cutting-edge mRNA technology to India, revolutionizing RNA
drugs development and manufacturing. This partnership is a significant step toward strengthening India’s preparedness for future pandemics while ensuring broader access to RNA-based innovations across LMICs."
This collaboration positions India as a hub for next-gen RNA-based vaccines, driving global partnerships for equitable healthcare.